KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biogen (BIIB) Accumulated Depreciation & Amortization (2016 - 2025)

Biogen (BIIB) has 17 years of Accumulated Depreciation & Amortization data on record, last reported at $779.9 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 15.85% year-over-year to $779.9 million; the TTM value through Dec 2025 reached $779.9 million, up 15.85%, while the annual FY2025 figure was $779.9 million, 15.85% up from the prior year.
  • Accumulated Depreciation & Amortization reached $779.9 million in Q4 2025 per BIIB's latest filing, up from $579.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $779.9 million in Q4 2025 and bottomed at $102.6 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $361.5 million, with a median of $353.8 million recorded in 2021.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 39.47% in 2022, then fell 21.52% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $487.7 million in 2021, then rose by 6.29% to $518.4 million in 2022, then decreased by 4.55% to $494.8 million in 2023, then surged by 36.05% to $673.2 million in 2024, then rose by 15.85% to $779.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $779.9 million in Q4 2025, $579.7 million in Q3 2025, and $377.5 million in Q2 2025.